Raltegravir (RAL) is metabolised by UGT1A1 and polymorphisms in the UGT1A1 gene have been associated with plasma concentrations in some but not all previous studies. This analysis represents the largest study to date for the effect of UGT1A1 polymorphisms on RAL PK/PD.
NEAT001/ANRS143, a randomised study (n=805 participants), demonstrated non-inferiority of first-line darunavir/ritonavir (DRV/r; 800/100 mg o.d) plus RAL (400 mg b.d) compared with DRV/r plus tenofovir/emtricitabine (245/200 mg o.d). Random, single samples were collected at weeks 4 and 24 post-therapy initiation for drug measurement. DNA was extracted and [i]UGT1A1[/i] polymorphisms genotyped using the Sequenom MassARRAY iPLEX. Nonlinear mixed effects modelling (NONMEM v. 7.3) was used to estimate PK parameters. Weight, age, sex, ethnicity and genotypes were investigated in the model for association with RAL apparent oral clearance (CL/F). Kaplan-Meier estimates and Cox regression were used to assess the relationship between virological failure by week 96 and [i]UGT1A1[/i] genotypes.
A total of 602 samples (n=313 week 4, n=289 week 24) from 349 patients were used in the model (n=264 with genotypes). UGT1A1 activity was defined as normal (*1/*1, *1/*36), reduced (*1/*6, *1/*28, *1/*37, *28/*36, *36/*37) or low (*28/*28, *28/*37, *37/*37). Although none of the covariates were statistically significant, RAL CL/F was reduced by 21% in patients with *28/*28 UGT1A1. A post-hoc analysis assessed the impact of UGT1A1*28 on predicted RAL AUC0-12 and C12 [low activity (n=40) vs normal/reduced activity (n=224)]. Geometric mean ratios (95% CI) were 1.35 (0.99-1.84; p=0.062) and 1.32 (0.99-1.77; p=0.062), respectively, suggesting minimal impact of UGT1A1*28 on RAL PK. By week 96, virological failure was seen in 16%, 22% and 2.5% of patients with normal, reduced and low UGT1A1 activity, respectively. Failure rates were lower in patients with low activity UGT1A1 (p=0.012; Figure). The relationship remained significant when adjusted for baseline CD4 count (p=0.048) but not when adjusted for baseline VL (p=0.082) or both CD4 and VL [HR (95% CI): 0.18 (0.02-1.30); p=0.08].
The NEAT001/ANRS143 study analysed UGT1A1 genotypes with the largest sample size to date and suggested little impact on RAL PK. However, UGT1A1 genotype may be a better correlate of RAL pharmacodynamics because of the high intra-subject variability in RAL PK.